Exagen’s Growth Potential Amid ASP Challenges: A Positive Long-Term Investment Outlook
I'm PortAI, I can summarize articles.
Exagen is viewed positively for long-term investment despite current average selling price (ASP) challenges. Revenue met expectations due to increased test volumes, which countered lower ASPs from a client shift to commercial insurance. Management aims for an ASP target of $600 and anticipates growth in test volumes. Analyst Daniel Brennan maintains an $18 price target, reflecting confidence in Exagen's value. He is a 5-star analyst with a 21.9% average return and a 57.81% success rate, covering the Healthcare sector.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments